Tag Archives: Eli Lilly

Pharma megamergers — against the spirit of the times?

Posted on April 23, 2014 by Alexander Szewczak

Here’s more on the Novartis-GSK-Lilly three way deal announced Tuesday.  As WSJ journalist Helen Thomas writes, the megamerger chill of dread felt when rumors of Pfizer’s stalking of AZ came to light last weekend may well be exorcized by this … Continue reading →

Posted in Fixing Big Pharma Research, Pharmaceutical Industry | Tagged , , , , , , | 1 Comment